July 20 (Reuters) - Synairgen Plc said on Monday
its drug helped reduce the risk of developing severe diseases in
hospitalised COVID-19 patients, according to data from a trial
of more than 100 people in the United Kingdom.
The trial, which used interferon beta, showed that patients
who were given Synairgen's formulation had a 79% lower risk of
developing severe disease compared to placebo.
Patients who received the drug, SNG001, were more than
twice as likely to recover from COVID-19 as those on placebo,
the company said.
Interferon beta is a naturally occurring protein, which
regulates the body's antiviral responses.
(Reporting by Aakash Jagadeesh Babu in Bengaluru; Editing by
Bernard Orr)